HHSN261201400038C;SBIR TOPIC 326 DEVELOPMENT OF NOVEL THERAPEUTIC AGENTS THAT TARGET CANCER STEM CELLS;PROJECT TITLE: CROSSING THE BBB AND TARGETING CSCS FOR GBM THERAPY;CONTRACT PERFORMANCE PERIOD 09

Information

• Research Project
• 8947614

• ApplicationId

  8947614

• Core Project Number

  N43CO000000

• Full Project Number

  261201400038C-0-0-1

• Serial Number

• FOA Number

• Sub Project Id

• Project Start Date

  9/15/2014 - 10 years ago

• Project End Date

  6/14/2015 - 9 years ago

• Program Officer Name

• Budget Start Date

  -

• Budget End Date

  -

• Fiscal Year

  2014

• Support Year

• Suffix

• Award Notice Date

  -

Organizations

• SynerGene Therapeutics, Inc.

Crossing the BBB and Targeting the CSCs for GBM Therapy

IC Name

• Activity

  N43

• Administering IC

  CA

• Application Type

• Direct Cost Amount

• Indirect Cost Amount

• Total Cost

  222900

• Sub Project Total Cost

• ARRA Funded

  False

• CFDA Code

  395

• Ed Inst. Type

• Funding ICs

  NCI:222900\

• Funding Mechanism

  SBIR/STTR Contracts

• Study Section

• Study Section Name

• Organization Name

  SYNERGENE THERAPEUTICS, INC.

• Organization Department

• Organization DUNS

  072898005

• Organization City

  Potomac

• Organization State

  MD

• Organization Country

  UNITED STATES

• Organization Zip Code

  208543963

• Organization District

  UNITED STATES